Brokerages Set CG Oncology, Inc. (NASDAQ:CGON) Price Target at $69.00
by Kim Johansen · The Markets DailyShares of CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) have earned an average recommendation of “Moderate Buy” from the fourteen brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have issued a buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $69.00.
Several analysts recently issued reports on CGON shares. Truist Financial raised their price target on CG Oncology from $66.00 to $75.00 and gave the stock a “buy” rating in a report on Tuesday, February 10th. Royal Bank Of Canada increased their target price on CG Oncology from $61.00 to $73.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 21st. HC Wainwright raised their target price on CG Oncology from $75.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Wedbush began coverage on shares of CG Oncology in a report on Thursday, December 11th. They set an “outperform” rating and a $70.00 price target for the company. Finally, Morgan Stanley set a $93.00 price target on shares of CG Oncology in a research report on Friday, January 9th.
Read Our Latest Stock Analysis on CG Oncology
CG Oncology Stock Up 5.8%
CGON opened at $67.68 on Wednesday. The firm has a market cap of $5.71 billion, a price-to-earnings ratio of -32.70 and a beta of 1.18. CG Oncology has a fifty-two week low of $14.80 and a fifty-two week high of $69.35. The company’s 50-day moving average price is $58.45 and its 200 day moving average price is $47.79.
CG Oncology (NASDAQ:CGON – Get Free Report) last issued its earnings results on Friday, February 27th. The company reported ($0.51) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.10. The company had revenue of $2.32 million during the quarter. Research analysts anticipate that CG Oncology will post -1.31 earnings per share for the current year.
Insider Transactions at CG Oncology
In other CG Oncology news, Director James Mulay sold 11,145 shares of the business’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $52.47, for a total transaction of $584,778.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Institutional Investors Weigh In On CG Oncology
Hedge funds have recently made changes to their positions in the business. PNC Financial Services Group Inc. increased its holdings in shares of CG Oncology by 15.2% during the second quarter. PNC Financial Services Group Inc. now owns 3,279 shares of the company’s stock valued at $85,000 after purchasing an additional 433 shares during the period. Comerica Bank raised its stake in shares of CG Oncology by 100.4% during the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after purchasing an additional 515 shares in the last quarter. LPL Financial LLC lifted its holdings in CG Oncology by 9.8% in the fourth quarter. LPL Financial LLC now owns 6,201 shares of the company’s stock worth $257,000 after purchasing an additional 551 shares during the period. Whittier Trust Co. of Nevada Inc. acquired a new stake in CG Oncology in the fourth quarter worth about $27,000. Finally, CWM LLC grew its position in CG Oncology by 10.9% in the 3rd quarter. CWM LLC now owns 6,865 shares of the company’s stock valued at $277,000 after buying an additional 672 shares in the last quarter. Institutional investors own 26.56% of the company’s stock.
About CG Oncology
CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.
Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.